
IRIDEX Corporation
IRIXNASDAQHealthcareMedical - Devices
Previous close
$0.7561
−$0.0055 · -0.72%
IRIX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
67
Undervalued
Momentum
48
Neutral
Sentiment
53
Mixed
Risk resilience
46
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteIRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Patrick Mercer
- Listed since
- Feb 16, 1996
- Employees
- 93
Market position
Day range
Current $0.7561
52-week range
Current $0.7561
- Open
- $0.7528
- Previous close
- $0.7616
- Volume
- 146.24K
- 2.2× average
- Average volume
- 66.44K
- Average daily volume
- Market cap
- 13.09M USD
- Beta
- 0.64
- Market reference 1
- 50-day average
- $0.9884
- -23.50% below average
- 200-day average
- $1.1201
- -32.50% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 18.61M USD
- P/E (TTM)
- -3.72×
- P/B (TTM)
- 3.61×
- P/S (TTM)
- 0.25×
- EV / EBITDA
- -6.57×
- Earnings yield
- -22.06%
- Free cash flow yield
- -11.23%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 36.23%
- Operating margin
- -5.39%
- Net margin
- -6.88%
- Return on equity
- -90.15%
- Return on assets
- -15.22%
- Return on invested capital
- -15.45%
Financial health
- Debt / equity
- 1.1×
- Current ratio
- 1.91×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 52.68M USD | 48.67M USD | 51.87M USD | 56.97M USD | 53.9M USD |
| Cost of goods sold | 33.37M USD | 29.17M USD | 30.06M USD | 31.6M USD | 31.07M USD |
| Gross profit | 19.31M USD | 19.5M USD | 21.81M USD | 25.37M USD | 22.83M USD |
| Research and development | 3.67M USD | 5.45M USD | 6.83M USD | 7.18M USD | 6.87M USD |
| Selling, general, and administrative | 18.13M USD | 22.36M USD | 24.99M USD | 25.74M USD | 23.5M USD |
| Operating expenses | 21.88M USD | 27.8M USD | 31.81M USD | 32.91M USD | 30.36M USD |
| Depreciation and amortization | 1.55M USD | 1.42M USD | 2.03M USD | 1.38M USD | 803K USD |
| Operating income | −2.57M USD | −8.3M USD | −10.01M USD | −7.54M USD | −7.53M USD |
| Net income | −4.44M USD | −8.91M USD | −9.57M USD | −7.55M USD | −5.23M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 6 misses, 2 met estimates
- Average EPS surprise
- -110.11%
- 11 comparable reports
- Latest EPS result
- -0.07
- Estimate -0.01 · Miss by 600.00%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
IRIX peers
ETFs holding IRIX
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research IRIXresearch.disclaimer







